LXEO
NASDAQ · Biotechnology
Lexeo Therapeutics Inc
$4.14
+0.06 (+1.47%)
Open$4.26
Previous Close$4.08
Day High$4.34
Day Low$4.12
52W High$10.99
52W Low$3.99
Volume—
Avg Volume706.2K
Market Cap341.31M
P/E Ratio—
EPS$-1.16
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+1,022.5% upside
Current
$4.14
$4.14
Target
$46.47
$46.47
$27.16
$46.47 avg
$57.70
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 110.56M | 98.68M | 97.87M |
| Net Income | 17.37M | 14.67M | 15.60M |
| Profit Margin | 15.7% | 14.9% | 15.9% |
| EBITDA | 19.93M | 19.03M | 18.02M |
| Free Cash Flow | 11.85M | 8.63M | 11.57M |
| Rev Growth | +16.0% | -2.8% | +7.5% |
| Debt/Equity | 0.49 | 0.46 | 0.54 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |